News for Venus Medtech (Hangzhou) Inc. (2500.HK)

HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed next-generation balloon-expandable dry-tissue transcatheter aortic valve replacement (TAVR) system, Venus-Vitae, successfully completed two inaugural implantations as part of its global multicenter pivotal trial, Venus-Vitae SMART-ALIGN, at Prince of Wales Hospital in Hong Kong, China.

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Venus Medtech disclosed governance and disclosure issues last May that forced it to halt trading in its stock six months later after an internal investigation.

Increasing prevalence of cardiac disorders and heart failure is one of the major factors driving transcatheter pulmonary valve replacement market revenue...

Global aortic valve replacement devices market is growing at a CAGR of 12.4% from 2022 to 2030....

/PRNewswire/ -- Recently, Venus Medtech (Hangzhou) Inc. ("Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart...

/PRNewswire/ -- The "Transcatheter Heart Valve Replacement Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of...

/PRNewswire/ -- The "China TAVR & TMV Market: Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to...

/PRNewswire/ -- On March 3, Venus Medtech (Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the...

Growing Adoption of Minimally Invasive Procedures Driving the Transcatheter Heart Valve Replacement Repair Market...

Transcatheter Heart Valve Replacement (TAVR) Market Growth Accelerating with Rising Volumes of TAVI Procedures. Self–expandable transcatheter aortic valves...